Regional Business Manager - Pacific Northwest

Intellia•Cambridge, MA

9d•Remote

About The Position

We are seeking an exceptional Sales Representative to lead the commercial launch of our groundbreaking in vivo CRISPR therapy for hereditary angioedema (HAE). This role represents a career defining opportunity to pioneer the commercialization of the first-ever, single treatment gene editing therapy. The successful candidate will be responsible for introducing healthcare providers to the first-ever in vivo CRISPR therapy, requiring sophisticated scientific communication, complex stakeholder management, and exceptional execution within a highly competitive rare disease market. This territory will cover Washington, Oregon, and Alaska.

Requirements

BS/BA in life sciences or a business-related field
5+ years of specialty pharmaceutical sales experience, preferably in rare diseases, immunology, or genetic medicines
Proven track record in rare disease commercialization with complex treatment paradigms and small patient populations
Previous experience with product launches, particularly first-in-class or novel mechanism therapies
Demonstrated success in long sales cycles (12-18 months) with multiple stakeholders and high-value transactions

Nice To Haves

Rare Disease, Gene therapy, and HAE market knowledge preferred but not necessary

Responsibilities

Develop and execute comprehensive territory plans targeting immunologists, allergists, emergency medicine physicians, and specialized HAE treatment centers
Identify and prioritize high-value accounts based on HAE patient volume, prescriber influence, and institutional capabilities
Establish trusted advisor relationships with key opinion leaders, clinical champions, and administrative decision-makers
Maintain robust sales pipeline tracking opportunities from initial awareness through patient treatment completion
Educate healthcare providers on in vivo CRISPR gene editing mechanisms, differentiating from ex vivo cell therapies and traditional treatments
Clearly articulate the unique mechanism of action compared to prophylactic treatments, complement inhibitors, and plasma-derived therapies
Present Phase III efficacy and safety data
Address misconceptions about CRISPR safety and differentiate from previous gene therapy launches
Educate healthcare providers about unmet needs affecting disease management and treatment burden
Maintain deep understanding of competitive landscape and emerging therapies
Articulate differentiated value propositions versus existing HAE treatments and other gene therapies
Proactively address concerns about CRISPR technology, permanent genetic modification, and single-treatment cost
Position organization as innovative leader with superior clinical acumen
Educate on the patient pathway from diagnosis confirmation through treatment administration
Coordinate with patient support hubs to ensure seamless patient experience and treatment access
Coordinate with Medical Science Liaisons to seamlessly address customers’ medical and clinical informational needs
Work closely with Field Reimbursement Managers on payer strategy and coverage optimization
Partner with strategic accounts team to understand referral patterns, site selection, and site activation for procurement and administration of the therapy